Chronotherapeutic diltiazem formulations and the administration thereof

• US 20060153914A1
• Filed: 03/09/2006
• Published: 07/13/2006
• Est. Priority Date: 12/10/1999
• Status: Abandoned Application

• Current Assignee: Biovail Laboratories International Srl (Bausch Health Cos., Inc.)
• Original Assignee: Biovail Laboratories International Srl (Bausch Health Cos., Inc.)
• Inventors: Maes, Paul Jose, Albert, Kenneth Stephen
• Application Number:
  US11/370,842
• Publication Number:
  US 20060153914A1
• Time in Patent Office: Days
• US Class Current: 424/468
• CPC Class Codes: A61K 31/553 having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
• CPC Class Codes: A61K 9/2081 with microcapsules or coated microparticles according to A61K9/50
• CPC Class Codes: A61K 9/5078 with drug-free core

Abstract

A controlled-release Galenical preparation of pharmaceutically acceptable Diltiazem including the pharmaceutically acceptable salts thereof, suitable for evening dosing every 24 hours containing from about 120 mg to about 540 mg or more (as desired) of the form of Diltiazem associated with excipients to provide controlled (sustained) release of the form of Diltiazem for providing a C_max of Diltiazem in the blood at between about 10 hours and about 15 hours after administration, the preparation comprising the form of Diltiazem in oral sustained-release dosage form in which the Diltiazem is adapted to be released after administration over a prolonged period of time and exhibits when given to humans (i) a higher bioavailability when given at night compared to when given in the morning without food according to FDA guidelines or criteria and (ii) bioequivalence when given in the morning with and without food according to the same FDA guidelines or criteria.

Claims

1. A chronotherapeutic extended release tablet dosage form comprising a dosage effective amount of diltiazem hydrochloride, which tablet dosage form is suitable for once-daily administration and which tablet dosage form when administered once daily provides for a Cmax of diltiazem in the blood to be attained between 10 and 15 hours after administration and wherein said extended release tablet dosage form comprises the following:

(i) a diltiazem hydrochloride containing core which contains an amount of diltiazem hydrochloride ranging from about 120 mg to about 540 mg; and

(ii) a membrane coating substantially surrounding said diltiazem containing core which membrane coating comprises a neutral acrylic polymer of acrylic acid ethyl ester and acrylic methyl ester and hydroxy propyl methyl cellulose (HPMC) and which membrane coating provides for the controlled release of said diltiazem hydrochloride from said core.

2. The extended release dosage form of claim 1 wherein the diltiazem hydrochloride in the core is comprised of at least one pellet or microgranule which comprises a neutral sugar sphere.

3. The extended release dosage form of claim 2 wherein said neutral acrylic polymer in said membrane coating comprises Eudragit NE 30D.

4. The extended release tablet of claim 3 wherein said coating is applied to said diltiazem core by spray coating.

5. The extended release tablet of claim 4 wherein the membrane coating which is applied by spray coating comprises at least one lubricant.

6. The extended release tablet of claim 5 wherein said at least one lubricant comprises talc and/or magnesium stearate.

7. The extended release tablet of claim 6 wherein the membrane coating further comprises at least one surfactant or emulsifier.

8. The extended release tablet of claim 7 wherein the surfactant comprises polysorbate 80.

9. The extended release tablet of claim 8 wherein the diltiazem HCl containing core comprises at least one binder.

10. The extended release tablet of claim 9 wherein said at least one binder comprises polyvinyl pyrollidone or a cellulose polymer.

11. The extended release tablet of claim 10 wherein said at least one binder comprises Povidone K30.

12. The extended release tablet of claim 11 wherein said extended release tablet is obtained by compressing said at least one membrane coated pellet or microgranule in the presence of at least one excipient.

13. The extended release tablet of claim 12 wherein said tablet is optionally coated.

14. The extended release tablet of claim 13 which comprises 120 mg of diltiazem HCl.

15. The extended release tablet of claim 13 which comprises 180 mg of diltiazem HCl.

16. The extended release tablet of claim 13 which comprises 240 mg of diltiazem HCl.

17. The extended release tablet of claim 13 which comprises 360 mg of diltiazem HCl.

18. The extended release tablet of claim 13 which comprises 420 mg of diltiazem HCl.

19. A method of treating angina comprising administering once daily in the evening an extended release tablet according to any one of claims 1-18.

20. A method of treating hypertension comprising administering once daily in the evening an extended release tablet according to any one of claims 1-18.

21. An extended release tablet containing an effective amount of diltiazem hydrochloride comprising:

(a) one or more pellets comprising diltiazem hydrochloride in an amount of from about 120 mg to about 540 mg, Povidone K30, and sugar;

(b) wherein each of said pellets has a membrane coating substantially surrounding each said pellet to form an extended release pellet, said membrane coating of the extended release pellet comprising Eudragit NE 30D, hydroxypropylmethylcellulose (HPMC), Polysorbate 80, magnesium stearate and talc;

(c) wherein the extended release pellets are combined with magnesium stearate and at least one other excipient, and are processed into an extended release tablet; and

(d) said extended release tablet is suitable for once daily administration, and when administered once daily provides for a Cmax of diltiazem in the blood at from about 10 to 15 hours after administration.

23. A method of treating hypertension comprising administering once daily an extended release tablet according to claim 21 or 22.

24. A method of treating angina comprising administering once daily an extended release tablet according to claim 21 or claim 22.

22. An extended release tablet containing an effective amount of diltiazem hydrochloride comprising:

(a) one or more pellets comprising diltiazem hydrochloride in an amount of from about 120 mg to about 540 mg, polyvinylpyrrolidone, and sugar;

(b) wherein each of said pellets has a membrane coating substantially surrounding said pellet to form an extended release pellet, said membrane coating of the extended release pellet comprising a water insoluble swellable neutral copolymer, hydroxypropylmethylcellulose (HPMC), a surfactant or emulsifier; and

one or more lubricants;

(c) wherein the extended release pellets are combined with a lubricant and at least one other excipient, and are processed into an extended release tablet;

(d) said extended release tablet is suitable for once daily administration, and when administered once daily provides for a Cmax of diltiazem in the blood at from about 10 and 15 hours after administration.